Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease
PLOS ONE · 09.03.2023 · 18 (3) · e0282852
DOI: 10.1371/journal.pone.0282852 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 09.03.2023. Verfasst von Su Jin Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.
Abstract (Originalsprache)
Introduction
We aimed to investigate the predictors of relapse in immunoglobulin G4-related disease (IgG4-RD), focusing on the serum IgG4 levels during initial treatment.
Methods
We retrospectively recruited 57 patients with IgG4-RD who were treated with immunosuppressants and elevated serum IgG4 levels in a tertiary hospital between January 2011 and December 2020. They were followed up for ≥ 6 months after initiation of immunosuppressive therapy. Clinical and laboratory findings including serum IgG4 levels (reference value: 6–121 mg/dL) were compared between relapsed ( n = 13) and non-relapsed ( n = 44) groups. Multivariate Cox regression analysis was used to assess the predictors for relapse. We performed a Kaplan–Meier analysis with a log-rank test to evaluate the cumulative relapse rate for two years.
Results
Median serum IgG4 levels at baseline were 321 mg/dL in the relapsed group and 299 mg/dL in the non-relapsed group. Serum IgG4 levels were normalized after six months in five (38.5%) relapsed and 28 (63.6%) non-relapsed patients. In multivariate Cox regression analysis, the normalization of serum IgG4 levels at six months was associated with a lower risk of relapse, with a hazard ratio of 0.232 ( p = 0.019). Central nervous system involvement was associated with the relapse, with a hazard ratio of 21.130 ( p = 0.015). The cumulative relapse rate for two years was lower in the normal serum IgG4 group at six months than in the elevated serum IgG4 group at six months ( p = 0.027).
Conclusion
Our study suggests that normalization of serum IgG4 levels during immunosuppressive treatment for IgG4-RD independently predicts relapse-free outcomes. Thus, monitoring serum IgG4 levels might be used as a marker of prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
- Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Information Medicine, Asan Medical Center, Seoul, South Korea.
ORCID-Profile: Yong-Gil Kim
Förderung
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Choi, S. J., Ahn, S. M., Oh, J. S., Hong, S., Lee, C. K., Yoo, B., & Kim, Y. G. (2023). Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease. PLOS ONE, 18(3), e0282852. https://doi.org/10.1371/journal.pone.0282852
Vancouver
Choi SJ, Ahn SM, Oh JS, Hong S, Lee CK, Yoo B, et al. Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease. PLOS ONE. 2023;18(3):e0282852. doi:10.1371/journal.pone.0282852
BibTeX
@article{Choi2023,
author = {Choi, Su Jin and Ahn, Soo Min and Oh, Ji Seon and Hong, Seokchan and Lee, Chang-Keun and Yoo, Bin and Kim, Yong-Gil},
title = {Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {3},
pages = {e0282852},
doi = {10.1371/journal.pone.0282852}
}
EUVIMED